Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily
Status:
Completed
Trial end date:
2011-10-06
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, dose response and safety of four doses of GSK2190915 in tablet form
(10mg, 30mg, 100mg and 300mg) administered once daily, over 8 weeks compared with placebo in
adolescent and adult subjects (12 years of age and older) with persistent asthma. These data
will form the basis for the selection of the optimal daily dose of GSK2190915 to be carried
forward in Phase III asthma studies. The study also includes Fluticasone Propionate
Inhalation Powder (100 mcg, twice daily) and Montelukast (10mg, once daily) to allow for an
exploratory analysis of the efficacy of GSK2190915 versus a low dose inhaled corticosteroid
and a leukotriene receptor antagonist.